|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Biochemistry
37:11516-11523
(1998)
|
|
PubMed id:
|
|
|
|
|
| |
|
Interactions of phenol and m-cresol in the insulin hexamer, and their effect on the association properties of B28 pro --> Asp insulin analogues.
|
|
J.L.Whittingham,
D.J.Edwards,
A.A.Antson,
J.M.Clarkson,
G.G.Dodson.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Insulin's natural tendency to form dimers and hexamers is significantly reduced
in a mutant insulin B28 Pro --> Asp, which has been designed as a monomeric,
rapid-acting hormone for therapeutic purposes. This molecule can be induced to
form zinc hexamers in the presence of small phenolic derivatives which are
routinely used as antimicrobial agents in insulin preparations. Two structures
of B28 Asp insulin have been determined from crystals grown in the presence of
phenol and m-cresol. In these crystals, insulin exists as R6 zinc hexamers
containing a number of phenol or m-cresol molecules associated with aromatic
side chains at the dimer-dimer interfaces. At the monomer-monomer interfaces,
the B28 Pro --> Asp mutation leads to increased conformational flexibility in
the B chain C termini, resulting in the loss of important intermolecular van der
Waals contacts, thus explaining the monomeric character of B28 Asp insulin. The
structure of a cross-linked derivative of B28 Asp insulin, containing an Ala-Lys
dipeptide linker between residues B30 Ala and A1 Gly, has also determined. This
forms an R6 zinc hexamer containing several m-cresol molecules. Of particular
interest in this structure are two m-cresol molecules whose binding disrupted
the beta-strand in one of the dimers. This observation suggests that the
cross-link introduces mechanical strain on the B chain C terminus, thereby
weakening the monomer-monomer interactions.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
C.Haupt,
M.Bereza,
S.T.Kumar,
B.Kieninger,
I.Morgado,
P.Hortschansky,
G.Fritz,
C.Röcken,
U.Horn,
and
M.Fändrich
(2011).
Pattern recognition with a fibril-specific antibody fragment reveals the surface variability of natural amyloid fibrils.
|
| |
J Mol Biol,
408,
529-540.
|
 |
|
|
|
|
 |
C.Poulsen,
D.Jacobsen,
and
L.Palm
(2008).
Effect of ethylenediamine on chemical degradation of insulin aspart in pharmaceutical solutions.
|
| |
Pharm Res,
25,
2534-2544.
|
 |
|
|
|
|
 |
H.Vashisth,
and
C.F.Abrams
(2008).
Ligand escape pathways and (un)binding free energy calculations for the hexameric insulin-phenol complex.
|
| |
Biophys J,
95,
4193-4204.
|
 |
|
|
|
|
 |
Q.X.Hua,
S.H.Nakagawa,
W.Jia,
K.Huang,
N.B.Phillips,
S.Q.Hu,
and
M.A.Weiss
(2008).
Design of an active ultrastable single-chain insulin analog: synthesis, structure, and therapeutic implications.
|
| |
J Biol Chem,
283,
14703-14716.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Z.L.Wan,
K.Huang,
S.Q.Hu,
J.Whittaker,
and
M.A.Weiss
(2008).
The structure of a mutant insulin uncouples receptor binding from protein allostery. An electrostatic block to the TR transition.
|
| |
J Biol Chem,
283,
21198-21210.
|
 |
|
|
|
|
 |
C.Kuei,
S.Sutton,
P.Bonaventure,
C.Pudiak,
J.Shelton,
J.Zhu,
D.Nepomuceno,
J.Wu,
J.Chen,
F.Kamme,
M.Seierstad,
M.D.Hack,
R.A.Bathgate,
M.A.Hossain,
J.D.Wade,
J.Atack,
T.W.Lovenberg,
and
C.Liu
(2007).
R3(BDelta23 27)R/I5 chimeric peptide, a selective antagonist for GPCR135 and GPCR142 over relaxin receptor LGR7: in vitro and in vivo characterization.
|
| |
J Biol Chem,
282,
25425-25435.
|
 |
|
|
|
|
 |
C.Poulsen,
L.Langkjaer,
and
C.Worsøe
(2007).
Precipitation of insulin aspart and insulin glulisine products used for continuous subcutaneous insulin infusion.
|
| |
Diabetes Technol Ther,
9,
26-35.
|
 |
|
|
|
|
 |
M.Norrman,
and
G.Schluckebier
(2007).
Crystallographic characterization of two novel crystal forms of human insulin induced by chaotropic agents and a shift in pH.
|
| |
BMC Struct Biol,
7,
83.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
R.H.Becker
(2007).
Insulin glulisine complementing basal insulins: a review of structure and activity.
|
| |
Diabetes Technol Ther,
9,
109-121.
|
 |
|
|
|
|
 |
O.V.Moroz,
G.G.Dodson,
K.S.Wilson,
E.Lukanidin,
and
I.B.Bronstein
(2003).
Multiple structural states of S100A12: A key to its functional diversity.
|
| |
Microsc Res Tech,
60,
581-592.
|
 |
|
|
|
|
 |
O.V.Moroz,
A.A.Antson,
E.J.Dodson,
H.J.Burrell,
S.J.Grist,
R.M.Lloyd,
N.J.Maitland,
G.G.Dodson,
K.S.Wilson,
E.Lukanidin,
and
I.B.Bronstein
(2002).
The structure of S100A12 in a hexameric form and its proposed role in receptor signalling.
|
| |
Acta Crystallogr D Biol Crystallogr,
58,
407-413.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
T.Kjeldsen,
S.Ludvigsen,
I.Diers,
P.Balschmidt,
A.R.Sorensen,
and
N.C.Kaarsholm
(2002).
Engineering-enhanced protein secretory expression in yeast with application to insulin.
|
| |
J Biol Chem,
277,
18245-18248.
|
 |
|
|
|
|
 |
J.Ye,
W.Chang,
and
D.Liang
(2001).
Crystal structure of destripeptide (B28-B30) insulin: implications for insulin dissociation.
|
| |
Biochim Biophys Acta,
1547,
18-25.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
G.D.Smith,
E.Ciszak,
L.A.Magrum,
W.A.Pangborn,
and
R.H.Blessing
(2000).
R6 hexameric insulin complexed with m-cresol or resorcinol.
|
| |
Acta Crystallogr D Biol Crystallogr,
56,
1541-1548.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
C.Clementi,
P.Carloni,
and
A.Maritan
(1999).
Protein design is a key factor for subunit-subunit association.
|
| |
Proc Natl Acad Sci U S A,
96,
9616-9621.
|
 |
|
|
|
|
 |
H.Berchtold,
and
R.Hilgenfeld
(1999).
Binding of phenol to R6 insulin hexamers.
|
| |
Biopolymers,
51,
165-172.
|
 |
|
|
|
|
 |
J.Brange,
and
A.Vølund
(1999).
Insulin analogs with improved pharmacokinetic profiles.
|
| |
Adv Drug Deliv Rev,
35,
307-335.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |